Filing Details
- Accession Number:
- 0001764013-22-000132
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-10-17 08:59:46
- Reporting Period:
- 2022-10-13
- Accepted Time:
- 2022-10-17 08:59:46
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1764013 | Immunovant Inc. | IMVT | Biological Products, (No Disgnostic Substances) (2836) | 832771572 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1796290 | G. Julia Butchko | C/O Immunovant, Inc. 320 W 37Th Street, 6Th Floor New York NY 10018 | Chief Dev. & Tech. Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2022-10-13 | 928 | $9.18 | 391,909 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 3,406 of these RSUs vested on October 1, 2022 and the remainder of the RSUs vest in quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.18 - $9.26 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.